Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 21 Dec 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.